ALZAI Health Corp. Obtains Exclusive Global License for AI-Powered Liver Disease Risk Detection Technology

Details and Scope of Exclusive License Agreement

ALZAI Health Corp. has entered into an exclusive worldwide license agreement with MOR Research Applications Ltd., the technology transfer company of Clalit Health Services, and Yeda Research, the technology transfer company of the Weizmann Institute of Science and Development Co. Ltd. Under this agreement, ALZAI gains an exclusive, worldwide, sublicensable license to develop, commercialize, and sublicense proprietary AI-driven liver disease risk detection technology.

The licensed technology stems from proprietary algorithms and intellectual property developed by leading Israeli healthcare and academic institutions. It is specifically designed to identify individuals potentially at risk for liver disease before clinical diagnosis. ALZAI plans to integrate this technology into its existing AI platform and advance commercialization through healthcare systems, life sciences organizations, pharmaceutical companies, and strategic commercial partners worldwide. The license is exclusive within the liver-associated diseases field.

Financial Terms and Royalty Structure

Per the agreement, ALZAI will pay customary royalties to MOR and Yeda based on future revenues generated from products derived from the licensed technology. Additionally, ALZAI will share a portion of revenues from sublicensing arrangements. Specific royalty rates and payment schedules were not disclosed.

This royalty framework aligns ALZAI’s payments with the commercial success of products and services developed from the licensed technology, fostering shared financial interests with licensors MOR and Yeda. ALZAI anticipates generating revenue both from direct commercialization and sublicensing to third parties.

Technology Features and Intended Use

The licensed AI technology aims to identify individuals at increased risk of liver-associated diseases such as cirrhosis and other chronic liver conditions by analyzing routine healthcare data. It supports earlier detection of at-risk individuals, aiding healthcare providers in prioritizing follow-up assessments, interventions, and disease management. ALZAI believes AI-driven analysis of routine healthcare data can enable earlier identification before advanced disease stages.

Current liver disease diagnostics often require specialized testing, imaging, or specialist referrals, posing barriers to large-scale population screening. By leveraging routine healthcare data and AI analysis, the technology seeks to overcome these challenges and facilitate efficient identification of individuals who may benefit from further evaluation and intervention. It is designed for integration into existing healthcare infrastructures, including electronic medical records, cloud environments, and enterprise healthcare platforms.

Strategic Expansion Beyond Alzheimer's Disease

This agreement marks a significant strategic expansion of ALZAI’s disease risk identification platform. Previously focused primarily on Alzheimer’s disease, ALZAI is now entering the liver disease risk identification market, positioning itself as a comprehensive AI-driven platform capable of supporting risk identification tools across multiple chronic diseases.

CEO Hayim Raclaw stated that this agreement represents a milestone in ALZAI’s evolution from a single-disease company to a broader AI-driven disease risk identification platform. ALZAI believes adding liver disease risk identification enhances its portfolio of AI-based disease prediction solutions using existing healthcare data, aligning with its long-term vision of building a multi-disease platform.

Global Challenge of Liver Disease

Liver disease is among the fastest-growing global healthcare challenges. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly Non-Alcoholic Fatty Liver Disease, poses a significant health burden affecting a large segment of the adult population worldwide. The announcement highlights that millions remain undiagnosed until advanced MASLD stages, underscoring a critical gap in early disease identification and intervention.

The prevalence and progressive nature of liver disease create a substantial market opportunity for risk identification solutions. Existing diagnostic methods often require specialized testing and imaging, limiting large-scale screening capacity. Early detection of individuals at elevated liver disease risk could enable timely intervention and improved disease management, addressing a major healthcare gap.

ALZAI Health Corp.’s Business Model and Platform

ALZAI Health Corp. develops non-invasive, AI-driven disease risk identification solutions utilizing routine healthcare data. Its proprietary platform identifies individuals at elevated disease risk prior to clinical diagnosis, enabling earlier intervention and improved patient outcomes. ALZAI’s technology has been validated on large healthcare datasets and is designed for seamless integration into existing healthcare systems.

The company’s business model focuses on developing and commercializing AI-based disease risk tools integrated into healthcare and enterprise platforms. ALZAI’s existing infrastructure and validation capabilities position it to advance development and commercialization of the licensed liver disease technology. Revenue streams are expected from direct commercialization and sublicensing with healthcare organizations, pharmaceutical firms, and strategic partners.

Commercialization Strategy and Market Potential

ALZAI plans to integrate the licensed technology into its AI platform and pursue commercialization via healthcare systems, life sciences organizations, pharmaceutical companies, and strategic partners globally. Leveraging its validation expertise and commercialization infrastructure, ALZAI aims to accelerate scalable solutions that help healthcare providers identify at-risk individuals.

The company believes combining the innovative liver disease technology with its AI infrastructure and commercialization strategy will expedite scalable solution development. Its multi-channel commercialization approach targets diverse customers across healthcare and life sciences sectors. Sublicensing offers additional revenue by enabling partners to incorporate the technology into their healthcare products and services.

Regulatory and Operational Considerations

Development and commercialization of the licensed technology will be subject to regulatory, privacy, and data protection requirements. Compliance with healthcare regulations, privacy laws, AI governance, cybersecurity, and healthcare data usage presents operational challenges. ALZAI must ensure adherence to applicable regulations as it develops and markets products incorporating the technology.

Intellectual property considerations include avoiding infringement on third-party rights. ALZAI’s ability to secure sufficient financial, technical, and operational resources will be critical for successful deployment. Competition from other disease risk identification providers also represents a significant consideration as ALZAI advances commercialization.

Forward-Looking Statements and Risks

The announcement contains forward-looking statements regarding anticipated benefits of the license agreement, ALZAI’s ability to develop and commercialize the technology, and its broader strategy to expand into additional disease-specific risk markets. These statements reflect management’s current expectations as of the announcement date.

Risks include the possibility that the technology may not perform as expected or gain commercial acceptance, technical or regulatory challenges, and inability to generate revenues or establish strategic partnerships on favorable terms. Broader economic, market, healthcare, regulatory, and industry conditions may also impact ALZAI’s success in developing and commercializing the licensed technology.